These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Estimation of direct medical costs of chronic obstructive pulmonary disease over 12 months]. Stâmbu I, Stoicescu IP. Pneumologia; 2013; 62(2):86-92. PubMed ID: 23894789 [Abstract] [Full Text] [Related]
4. Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching. Akazawa M, Biddle AK, Stearns SC. Clin Ther; 2008; 30 Spec No():1003-16. PubMed ID: 18640475 [Abstract] [Full Text] [Related]
5. Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore. Lee KH, Phua J, Lim TK. Respir Med; 2006 Dec; 100(12):2190-6. PubMed ID: 16635566 [Abstract] [Full Text] [Related]
6. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS. COPD; 2010 Jun; 7(3):214-28. PubMed ID: 20486821 [Abstract] [Full Text] [Related]
7. [Introduction to asthma and chronic obstructive pulmonary disease pharmacoeconomics]. Jahnz-Rózyk K. Pol Merkur Lekarski; 2004 May; 16 Suppl 1():5-6, 8. PubMed ID: 15524004 [Abstract] [Full Text] [Related]
8. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities. Simoni-Wastila L, Blanchette CM, Qian J, Yang HW, Zhao L, Zuckerman IH, Pak GH, Silver H, Dalal AA. Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302 [Abstract] [Full Text] [Related]
9. Clinical and economic analysis of antimicrobial therapy of chronic obstructive pulmonary disease exacerbations. Simoens S, Decramer M, De Coster S, Celis G, Laekeman G. Int J Clin Pract; 2007 Feb; 61(2):200-6. PubMed ID: 17263707 [Abstract] [Full Text] [Related]
10. [Treatment of exacerbations of chronic obstructive pulmonary disease]. Urso DL, Luchetti L. Recenti Prog Med; 2007 Mar; 98(3):181-3. PubMed ID: 17484166 [Abstract] [Full Text] [Related]
11. [Chronic-obstructive pulmonary disease. Medical treatment]. Randerath W, Galetke W, Karl-Heinz R. Med Monatsschr Pharm; 2002 May; 25(5):150-8; quiz 158, 168. PubMed ID: 12050920 [No Abstract] [Full Text] [Related]
15. Bronchodilator reliever use and its association with the economic and humanistic burden of COPD: a propensity-matched study. Punekar YS, Naya I, Small M, Holbrook T, Wood R, Mullerova H, Valle M. J Med Econ; 2017 Jan; 20(1):28-36. PubMed ID: 27564685 [Abstract] [Full Text] [Related]
16. Health care use and economic burden of patients with diagnosed chronic obstructive pulmonary disease in Korea. Kim C, Yoo KH, Rhee CK, Yoon HK, Kim YS, Lee SW, Oh YM, Lee SD, Lee JH, Kim KJ, Kim JH, Park YB. Int J Tuberc Lung Dis; 2014 Jun; 18(6):737-43. PubMed ID: 24903947 [Abstract] [Full Text] [Related]